Your browser doesn't support javascript.
loading
Type 2 diabetes and colorectal cancer survival: The multiethnic cohort.
Amshoff, Yvette; Maskarinec, Gertraud; Shvetsov, Yurii B; Raquinio, Phyllis H; Grandinetti, Andrew; Setiawan, Veronica W; Haiman, Christopher A; Le Marchand, Loïc.
Afiliação
  • Amshoff Y; Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI.
  • Maskarinec G; Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI.
  • Shvetsov YB; Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI.
  • Raquinio PH; Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI.
  • Grandinetti A; Office of Public Health Studies, University of Hawaii, Honolulu, HI.
  • Setiawan VW; Department of Preventive Medicine, Keck School of Medicine, and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA.
  • Haiman CA; Department of Preventive Medicine, Keck School of Medicine, and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA.
  • Le Marchand L; Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI.
Int J Cancer ; 143(2): 263-268, 2018 07 15.
Article em En | MEDLINE | ID: mdl-29441528
This analysis examined type 2 diabetes (T2D) as a predictor of colorectal cancer (CRC) survival within the Multiethnic Cohort Study. Registry linkages in Hawaii and California identified 5,284 incident CRC cases. After exclusion of cases with pre-existing cancer diagnosis within 1 year and systemic disease, the analytic dataset had 3,913 cases with 1,800 all-cause and 678 CRC-specific deaths after a mean follow-up of 9.3 ± 5.2 years. Among CRC cases, 707 were diagnosed with T2D 8.9 ± 5.3 years before CRC. Cox regression with age as time metric was applied to estimate hazard ratios (HR) and 95% confidence intervals (CI) for T2D status as predictor of CRC-specific and all-cause survival while adjusting for known confounders. Overall, CRC-specific survival was not associated with pre-existing T2D (HR = 0.84; 95% CI = 0.67-1.07). However, a significant interaction was seen for comorbidity (pinteraction  = 0.03) with better survival among those without pre-existing conditions (HR = 0.49; 95% CI = 0.25-0.96) while no association was seen in patients with comorbid conditions. All-cause mortality was also not related to pre-existing T2D (HR = 1.11; 95% CI = 0.98-1.27), but significantly elevated for individuals with T2D reporting comorbid conditions (HR = 1.36; 95% CI = 1.19-1.56). Stratification by T2D duration suggested higher CRC-specific and all-cause mortality among participants with a T2D history of ≥10 than <10 years. The findings were consistent across sex and ethnic subgroups. In contrast to previous reports, pre-existing T2D had no influence on disease-specific and all-cause survival among CRC patients. Only participants with additional comorbidity and possibly those with long T2D duration experienced higher mortality related to T2D.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Diabetes Mellitus Tipo 2 Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged País como assunto: America do norte Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Diabetes Mellitus Tipo 2 Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged País como assunto: America do norte Idioma: En Ano de publicação: 2018 Tipo de documento: Article